MAYO CLINIC
Q2 2023 Form 13-F
ROCHESTER, MINNESOTA
CIK 0001318153
· Institutional investment manager
$97.4M Reported Value Total
Reported value
$97.4M
Quarter over quarter
+7.4%
Holdings
11
Top-10 concentration
99.9%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Paul A Gorman
Chief Investment Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | August 09, 2023 |
| Form | 13F-HR |
| Reported value | $97.4M |
| Positions | 11 |
| Change in reported value | -20.0% |
| New positions | 0 |
| Exited positions | 2 |
| Position turnover | 15.4% |
| Top-10 concentration | 99.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2024 13F
Filed Nov 12, 2024
|
3 | $2.9M |
|
Q2 2024 13F
Filed Aug 12, 2024
|
4 | $3.0M |
|
Q1 2024 13F
Filed May 13, 2024
|
5 | $6.1M |
|
Q4 2023 13F
Filed Feb 13, 2024
|
7 | $16.2M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
9 | $51.9M |
|
Q2 2023 13F
Filed Aug 9, 2023
|
11 | $97.4M |
|
Q1 2023 13F
Filed May 5, 2023
|
13 | $121.8M |
|
Q4 2022 13F
Filed Jan 26, 2023
|
13 | $188.8M |
|
Q2 2021 13F
Filed Aug 12, 2021
|
9 | $90.4M |
|
Q1 2021 13F
Filed May 13, 2021
|
8 | $86.9M |
|
Q4 2020 13F
Filed Feb 11, 2021
|
9 | $83.1M |
|
Q3 2020 13F
Filed Nov 12, 2020
|
9 | $74.2M |
|
Q2 2020 13F
Filed Aug 13, 2020
|
8 | $104.5M |
|
Q1 2020 13F
Filed Apr 24, 2020
|
7 | $39.5M |
|
Q4 2019 13F
Filed Feb 12, 2020
|
8 | $88.2M |
Top 11 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ACWI MSCI ACWI ETF | $80.0M | 82.12% |
| 2 | BSM BLACK STONE MINERALS | $10.3M | 10.54% |
| 3 | ZNTL Zentalis Pharmaceuticals Inc | $5.3M | 5.42% |
| 4 | MIRO Miromatrix Med Inc | $335.9K | 0.34% |
| 5 | UNBX UNITY BIOTECHNOLOGY INC | $316.4K | 0.32% |
| 6 | EXAS Exact Sciences | $297.4K | 0.31% |
| 7 | CLPT Clearpoint Neuro Inc | $275.9K | 0.28% |
| 8 | SCLX Scilex Holding Co | $235.6K | 0.24% |
| 9 | NMTC Neuroone Medical Technologies | $218.1K | 0.22% |
| 10 | BSGM BIOSIG TECH INC | $126.1K | 0.13% |
| 11 | EVLO EVELO BIOSCIENCES INC | $73.4K | 0.08% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.